Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Posts Flat Q4 Revenues

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its fourth-quarter revenues were essentially flat with Q4 2008 but managed to beat analysts' consensus estimate.

The Waltham, Mass.-based firm generated total revenues of $498.3 million for the three-month period ended Jan. 3, 2010, compared to $500 million in sales for the fourth quarter of 2008. It noted that currency translation and acquisitions had a favorable impact on revenues of 4 percent and 1 percent, respectively.

Sales for its Human Health segment were $194.2 million, up slightly from $193.9 million, while sales for its Environmental Health segment were 4304.1 million versus $306 million for Q4 2008.

PerkinElmer's profit for the quarter was $39.9 million, or $.34 per share, compared to $30.7 million, or $.26 per share, for Q4 2008. On an adjusted basis, its EPS was $.43 versus $.46.

PerkinElmer beat analysts' consensus estimates for revenues of $479.5 million and EPS of $.41.

The firm's R&D spending increased 9 percent to $27.6 million from $25.3 million, and its SG&A spending increased 7 percent to $129.7 million from $121 million.

For full-year 2009, PerkinElmer brought in total revenues of $1.8 billion compared to $1.96 billion for 2008. Its Human Health segment had sales of $736.5 million versus $774.6 million for 2008, while its Environmental Health segment had sales of $1.08 billion, down from $1.19 billion.

Its full-year net income was $85.6 million, or $.73 per share, down from $126.4 million, or $1.07 per share. On an adjusted basis, its EPS was $1.27, down from $1.41.

PerkinElmer finished the year with cash and cash equivalents of $179.7 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.